Ruqaiya Shahid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruqaiya Shahid has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Adnan Sami
University of the Punjab Quaid-i-Azam Campus: University of the Punjab
1 shared publication Alina Rizvi
Dow International Medical College [DIMC], Dow University of Health Sciences, Karachi, Pakistan
1 shared publicationD. Mirchandani
Saskatoon Cancer Center, University of Saskatchewa, Saskatoon, SK, Canada; Dow University of Health Sciences, Karachi, Pakistan
1 shared publicationD. Popkin
Saskatoon Cancer Center, University of Saskatchewa, Saskatoon, SK, Canada; Dow University of Health Sciences, Karachi, Pakistan
1 shared publication- Farah Fatima Abbas
Department of Pathology, Dow International Medical College (DIMC), Dow University of Health Sciences,Karachi, Pakistan
1 shared publication H. Bhatt
Community Health and Epidemiology and
1 shared publication
Latest Publications
- Open Access
- 16 April 2026
- Published by IntechOpen
Clinical and Radio-pathological Spectrum of Bone Tumors: Review and Update
Bone tumors (BTs) range from benign to malignant and differ in pathogenesis according to the origin of the skeletal tissue, that is, osteogenic, chondrogenic, fibrogenic, vascular, osteoclastic giant cell-rich, hematopoietic neoplasm, notochordal, and other mesenchymal tumors of bone. The location, site, and type of BT vary according to the age of the patient. The confirmatory diagnosis for malignant ones involves the combined radiological and histopathological approach, that is, radiograph, MRI, bone scan, tissue biopsy with gross specimen, microscopy, molecular biology, and immunohistochemistry (IHC). MRI is useful to assess the local extent and staging, recurrent/residual disease, and post-operative complications. CT is indicated to evaluate only few BT because of the ionizing radiation. Contrast CT chest and bone scans are indicated for metastatic work-up. Management ranges from a conservative approach, wide local excision, en bloc resection, limb salvage surgery/amputation to chemotherapy depending upon molecular markers and radiotherapy. In this chapter, authors shed the spotlight on BT, based on multi-modality and multidisciplinary collaborative pragmatic approach, with updates from current literature.
- 16 April 2026
- Published by IntechOpen
Open AccessClinical and Radio-pathological Spectrum of Bone Tumors: Review and Update
Bone tumors (BTs) range from benign to malignant and differ in pathogenesis according to the origin of the skeletal tissue, that is, osteogenic, chondrogenic, fibrogenic, vascular, osteoclastic giant cell-rich, hematopoietic neoplasm, notochordal, and other mesenchymal tumors of bone. The location, site, and type of BT vary according to the age of the patient. The confirmatory diagnosis for malignant ones involves the combined radiological and histopathological approach, that is, radiograph, MRI, bone scan, tissue biopsy with gross specimen, microscopy, molecular biology, and immunohistochemistry (IHC). MRI is useful to assess the local extent and staging, recurrent/residual disease, and post-operative complications. CT is indicated to evaluate only few BT because of the ionizing radiation. Contrast CT chest and bone scans are indicated for metastatic work-up. Management ranges from a conservative approach, wide local excision, en bloc resection, limb salvage surgery/amputation to chemotherapy depending upon molecular markers and radiotherapy. In this chapter, authors shed the spotlight on BT, based on multi-modality and multidisciplinary collaborative pragmatic approach, with updates from current literature.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 25 (6) , 773-778
From Reactive Hyperplasia to Neoplastic Changes: Histopathological Insights into Lymphadenopathy
Background: Inflammation, infection, autoimmune diseases, or malignancy can cause the abnormal proliferation of lymphocytes; therefore, clinicians should always take detailed history and physical examination to screen the patient for lymphadenopathy. Objectives: The aim and objective of the current study was to assess the pattern of diseases causing lymphadenopathies in the Pakistani Population. Methodology: The current study was a cross-sectional study. Data were obtained from existing patient records from Dow Diagnostic Research and Reference Laboratory [DDRRL]-Dow University of Health Sciences [DUHS] from Jan 2020 to Dec 2022. Patients undergoing chemotherapy and biopsies with poor preservation and inconclusive diagnosis were excluded from the study, while patients of any age, gender, and various sites of lymphadenopathy were included in this study. Ethical approval was obtained from the ethical Review Board [IRB] of Dow University of Health Sciences [DUHS]. Results: A total of 675 FNAC and lymph node biopsies of lymph nodes were obtained. Age, location, and gender were taken into consideration when analyzing the lymph node biopsy materials of these patients. There were 200 [29.62%] males and 475 [70.37%] females. The age range of the patients was 1 year to 80 years, and the mean [SD] age of the patients was 33.76 ± 17.54 years. Conclusion: In the current study, we aim to provide guidance to the clinician on initial diagnostic laboratory testing, imaging, and the potential need for biopsy by evaluating the pattern of diseases causing lymphadenopathy in our population.
- 1 June 2025
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 25 (6) , 773-778
From Reactive Hyperplasia to Neoplastic Changes: Histopathological Insights into Lymphadenopathy
Background: Inflammation, infection, autoimmune diseases, or malignancy can cause the abnormal proliferation of lymphocytes; therefore, clinicians should always take detailed history and physical examination to screen the patient for lymphadenopathy. Objectives: The aim and objective of the current study was to assess the pattern of diseases causing lymphadenopathies in the Pakistani Population. Methodology: The current study was a cross-sectional study. Data were obtained from existing patient records from Dow Diagnostic Research and Reference Laboratory [DDRRL]-Dow University of Health Sciences [DUHS] from Jan 2020 to Dec 2022. Patients undergoing chemotherapy and biopsies with poor preservation and inconclusive diagnosis were excluded from the study, while patients of any age, gender, and various sites of lymphadenopathy were included in this study. Ethical approval was obtained from the ethical Review Board [IRB] of Dow University of Health Sciences [DUHS]. Results: A total of 675 FNAC and lymph node biopsies of lymph nodes were obtained. Age, location, and gender were taken into consideration when analyzing the lymph node biopsy materials of these patients. There were 200 [29.62%] males and 475 [70.37%] females. The age range of the patients was 1 year to 80 years, and the mean [SD] age of the patients was 33.76 ± 17.54 years. Conclusion: In the current study, we aim to provide guidance to the clinician on initial diagnostic laboratory testing, imaging, and the potential need for biopsy by evaluating the pattern of diseases causing lymphadenopathy in our population.
- Open Access
- 11 August 2021
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 17 (1) , 14-27
Serum biomarkers for the prediction and diagnosis of preeclampsia: A meta-analysis
- 11 August 2021
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 17 (1) , 14-27
Open AccessSerum biomarkers for the prediction and diagnosis of preeclampsia: A meta-analysis
- 23 May 2012
- Published by S. Karger AG in Oncology
- Vol. 82 (6) , 327-332
Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?
Objectives: Chemotherapy increases the risk of thromboembolism in patients with cancer. Although thrombocytopenia is a known side effect of chemotherapy, reactive thrombocytosis related to chemotherapy is uncommonly reported. The present study aimed to determine the incidence of gemcitabine-related thrombocytosis and the associated risk of thromboembolism. Methods: Medical records of 250 consecutive patients with a malignant disease who received gemcitabine-based therapy were reviewed. A multivariate analysis was done to determine factors associated with thromboembolism. Results: A total of 220 eligible patients with a median age of 63 years (range 26–83) were identified. Of these 220 patients, 95% had advanced malignancy and 59% had received prior chemotherapy. A total of 69% of patients received a platinum combination. In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 109/l (range 457–1,385). Twenty-three of the 220 patients experienced a vascular event within 6 weeks of treatment. Eleven patients with thrombocytosis experienced a vascular event compared with 10 patients without thrombocytosis (not significant). On multivariate analysis, leukocytosis (odds ratio 5.8, 95% confidence interval 2.1–15.8) and comorbid illnesses (odds ratio 4.1, 95% confidence interval 1.4–12.6) were correlated with thromboembolism. Conclusions: Although gemcitabine-based therapy has been associated with an increased incidence of thrombocytosis, it does not increase the risk of thromboembolism in cancer patients. Leukocytosis and comorbid illnesses do increase the risk of thromboembolism.
- 23 May 2012
- Published by S. Karger AG in Oncology
- Vol. 82 (6) , 327-332
Chemotherapy-Related Thrombocytosis: Does It Increase the Risk of Thromboembolism?
Objectives: Chemotherapy increases the risk of thromboembolism in patients with cancer. Although thrombocytopenia is a known side effect of chemotherapy, reactive thrombocytosis related to chemotherapy is uncommonly reported. The present study aimed to determine the incidence of gemcitabine-related thrombocytosis and the associated risk of thromboembolism. Methods: Medical records of 250 consecutive patients with a malignant disease who received gemcitabine-based therapy were reviewed. A multivariate analysis was done to determine factors associated with thromboembolism. Results: A total of 220 eligible patients with a median age of 63 years (range 26–83) were identified. Of these 220 patients, 95% had advanced malignancy and 59% had received prior chemotherapy. A total of 69% of patients received a platinum combination. In all, 46% patients experienced thrombocytosis following chemotherapy, with a median platelet count of 632 × 109/l (range 457–1,385). Twenty-three of the 220 patients experienced a vascular event within 6 weeks of treatment. Eleven patients with thrombocytosis experienced a vascular event compared with 10 patients without thrombocytosis (not significant). On multivariate analysis, leukocytosis (odds ratio 5.8, 95% confidence interval 2.1–15.8) and comorbid illnesses (odds ratio 4.1, 95% confidence interval 1.4–12.6) were correlated with thromboembolism. Conclusions: Although gemcitabine-based therapy has been associated with an increased incidence of thrombocytosis, it does not increase the risk of thromboembolism in cancer patients. Leukocytosis and comorbid illnesses do increase the risk of thromboembolism.
- 20 June 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (18_suppl) , 6091
Gemcitabine-related thrombocytosis: Does it increase the risk of thrombosis?
6091 Background: Gemcitabine is an antimetabolite agent that has demonstrated activity in various solid and hematological malignancies. Although thrombocytopenia is a known side effect, gemcitabine-related thrombocytosis has been uncommonly reported. Chemotherapy increases the risk of thrombo-embolism in patients with cancer. The study aimed to identify the incidence of gemcitabine-related thrombocytosis and to determine whether it has been associated with an increased risk of thrombo-embolism. Methods: Medical records of 175 consecutive adults patients with a malignant disease who received gemcitabine at Saskatoon Cancer Center were reviewed. Patients with history of prior thrombo-embolism or with baseline thrombocytosis were excluded. Fisher’s Exact test was done for statistical analysis. Results: 149 eligible patients with median age of 62 (26–83) and M:F of 1.01:1 were identified. 141 (95%) patients had advanced malignancy and 61 (41%) had received prior chemotherapy. 106 (71%) patients received combination of chemotherapy and 95% of those patients received gemcitabine in combination with a platinum compound. Median number of cycle was 3 (1–8). Median platelets count prior to commencement of gemcitabine was 285 × 109 (44–449). 83 (56%) patients experienced thrombocytopenia whereas 69 (46%) patients experienced thrombocytosis within 3 weeks of treatment with gemcitabine. Median post-gemcitabine platelet count in patients with thrombocytosis was 622 × 109 (457–1385). 15 (10%) patients experienced thrombocytosis with each cycle of gemcitabine. Median duration of thrombocytosis was 2 weeks (0.5−5). 13 (9%) of 149 patients experienced a vascular event (venous, n=9; arterial, n=4) within 6 weeks of treatment with gemcitabine. Median platelet count prior to the vascular event was 268 × 109 (79–669). All except one patient had advanced malignancy and 85% had received combination of chemotherapy. 5 of 69 (7%) patients with thrombocytosis experienced a vascular event compared with 8 of 80 (10%) patients without thrombocytosis (p=0.77). Conclusions: Gemcitabine has been associated with an increased incidence of thrombocytosis. However gemcitabine-related thrombocytosis is a transient phenomenon and has not been associated with an increased risk of a vascular event. No significant financial relationships to disclose.
- 20 June 2006
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (18_suppl) , 6091
Gemcitabine-related thrombocytosis: Does it increase the risk of thrombosis?
6091 Background: Gemcitabine is an antimetabolite agent that has demonstrated activity in various solid and hematological malignancies. Although thrombocytopenia is a known side effect, gemcitabine-related thrombocytosis has been uncommonly reported. Chemotherapy increases the risk of thrombo-embolism in patients with cancer. The study aimed to identify the incidence of gemcitabine-related thrombocytosis and to determine whether it has been associated with an increased risk of thrombo-embolism. Methods: Medical records of 175 consecutive adults patients with a malignant disease who received gemcitabine at Saskatoon Cancer Center were reviewed. Patients with history of prior thrombo-embolism or with baseline thrombocytosis were excluded. Fisher’s Exact test was done for statistical analysis. Results: 149 eligible patients with median age of 62 (26–83) and M:F of 1.01:1 were identified. 141 (95%) patients had advanced malignancy and 61 (41%) had received prior chemotherapy. 106 (71%) patients received combination of chemotherapy and 95% of those patients received gemcitabine in combination with a platinum compound. Median number of cycle was 3 (1–8). Median platelets count prior to commencement of gemcitabine was 285 × 109 (44–449). 83 (56%) patients experienced thrombocytopenia whereas 69 (46%) patients experienced thrombocytosis within 3 weeks of treatment with gemcitabine. Median post-gemcitabine platelet count in patients with thrombocytosis was 622 × 109 (457–1385). 15 (10%) patients experienced thrombocytosis with each cycle of gemcitabine. Median duration of thrombocytosis was 2 weeks (0.5−5). 13 (9%) of 149 patients experienced a vascular event (venous, n=9; arterial, n=4) within 6 weeks of treatment with gemcitabine. Median platelet count prior to the vascular event was 268 × 109 (79–669). All except one patient had advanced malignancy and 85% had received combination of chemotherapy. 5 of 69 (7%) patients with thrombocytosis experienced a vascular event compared with 8 of 80 (10%) patients without thrombocytosis (p=0.77). Conclusions: Gemcitabine has been associated with an increased incidence of thrombocytosis. However gemcitabine-related thrombocytosis is a transient phenomenon and has not been associated with an increased risk of a vascular event. No significant financial relationships to disclose.